Prelude Therapeutics Incorporated (PRLD) Revenue History
Annual and quarterly revenue from 2018 to present
PRLD Revenue Over Time (2018–2025)
PRLD Revenue Growth History
1 of 1 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +73.4%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $4.6M | — |
| Q4 2025 | $5.6M | +41.0% |
| Q3 2025 | $6.5M | +116.7% |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $4.0M | — |
| Q3 2024 | $3.0M | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
PRLD Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 23, 2026, Prelude Therapeutics Incorporated (PRLD) generated trailing twelve-month (TTM) revenue of $16.7 million. The most recent quarter (Q1 2026) recorded $4.6 million in revenue, down 18.8% sequentially.
Historical Growth Trajectory
PRLD's historical revenue data shows various trends over time. Prelude Therapeutics Incorporated's highest annual revenue of $12.1 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), ARVN (-79.1% YoY), and AUPH (+20.6% YoY). Compare PRLD vs KYMR →
PRLD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRLDCurrent | $17M | - | - | -861.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARVN | $263M | -79.1% | +58.9% | -43.8% | |
 AUPH | $283M | +20.6% | +41.4% | 37.1% |
PRLD Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.1M | +73.4% | $10.4M | 85.9% | $-104,566,000 | -861.3% |
| 2024 | $7.0M | - | $7.0M | 100.0% | $-139,714,000 | -1995.9% |
| 2023 | $0 | - | $0 | - | $-132,276,999 | - |
| 2022 | $0 | - | $0 | - | $-123,540,000 | - |
| 2021 | $0 | - | $0 | - | $-113,735,000 | - |
| 2020 | $0 | - | $0 | - | $-58,763,000 | - |
| 2019 | $0 | - | $0 | - | $-28,109,000 | - |
| 2018 | $0 | - | $-149,000 | - | $-14,975,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PRLD — Frequently Asked Questions
Quick answers to the most common questions about buying PRLD stock.
Is PRLD's revenue growth accelerating or slowing?
PRLD TTM revenue: $17M. YoY growth: N/A. 5-year CAGR: N/A.
What is PRLD's revenue history from 2018 to 2026?
Prelude Therapeutics Incorporated (PRLD) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $17M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is PRLD's long-term revenue growth rate (CAGR)?
Prelude Therapeutics Incorporated's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PRLD.
Why does PRLD's quarterly revenue fluctuate?
PRLD quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Prelude Therapeutics Incorporated's revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is PRLD's revenue distributed by segment?
PRLD reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does PRLD's revenue compare to industry peers?
Prelude Therapeutics Incorporated (PRLD) with TTM revenue of $17M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.